Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors

NCT06727617 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

134

Enrollment

OTHER

Sponsor class

Conditions

Cervical Cancers

Interventions

DRUG: Serplulimab
DRUG: Chemotherapy
RADIATION: radiotherapy

Sponsor

Tianjin Medical University Cancer Institute and Hospital